1月29日 - ** 药物开发商 Unicycive Therapeutics UNCY.O 股价盘前上涨 9.5% 至 7.69 美元
** 该公司称， (link) FDA接受了其重新提交的用于治疗透析患者高磷酸盐水平的碳酸氧黄檀药片的申请以进行审查。
** 公司称，晚期肾病患者体内高磷酸盐水平的出现，是由于身体无法排出多余的矿物质。
** 公司称美国食品及药物管理局未对该药的安全性或有效性提出初步担忧；预计将于 6 月 27 日做出决定
** 公司称，UNCY 的药物旨在减轻药片负担，帮助患者坚持治疗；如获批准，可能在今年晚些时候上市
** 2025 年股价下跌约 27%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.